|Dr. Mondher Mahjoubi||Chairman of Exec. Board & CEO||778.13k||N/A||1958|
|Mr. Yannis Morel||Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board||359.04k||N/A||1973|
|Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA||Exec. VP of Fin. & Corp. Strategy||300.65k||N/A||1978|
|Dr. Herve Brailly||Co-Founder & Chairman of Supervisory Board||N/A||N/A||1961|
|Dr. FranÃ§ois RomagnÃ©||Founder||N/A||N/A||1964|
|Mr. Eric Vivier D.V.M., M.B.A., Ph.D.||Founder, Sr. VP & Chief Scientific Officer||N/A||N/A||1964|
|Dr. Marc Bonneville||Founder||N/A||N/A||1960|
|Mr. Jean Jacques FourniÃ© Ph.D.||Founder||N/A||N/A||N/A|
|Mr. Alessandro Moretta M.D., Ph.D.||Founder||N/A||N/A||N/A|
|Mr. Frederic Lombard M.B.A.||Sr. VP & CFO||N/A||N/A||N/A|
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sÃ©zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Innate Pharma S.A.’s ISS Governance QualityScore as of July 1, 2021 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 3; Compensation: 10.